Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Erratum to: Hydrolysis and Dissolution of Amyloids by Catabodies.

Meretoja VV, Paul S, Planque SA.

Methods Mol Biol. 2017;1643:E1. doi: 10.1007/978-1-4939-7180-0_16. No abstract available.

PMID:
28836187
2.

Hydrolysis and Dissolution of Amyloids by Catabodies.

Meretoja VV, Paul S, Planque SA.

Methods Mol Biol. 2017;1643:111-134. doi: 10.1007/978-1-4939-7180-0_9. Erratum in: Methods Mol Biol. 2017;1643:E1.

PMID:
28667533
3.

Specific amyloid β clearance by a catalytic antibody construct.

Planque SA, Nishiyama Y, Sonoda S, Lin Y, Taguchi H, Hara M, Kolodziej S, Mitsuda Y, Gonzalez V, Sait HB, Fukuchi K, Massey RJ, Friedland RP, O'Nuallain B, Sigurdsson EM, Paul S.

J Biol Chem. 2015 Apr 17;290(16):10229-41. doi: 10.1074/jbc.M115.641738. Epub 2015 Feb 27.

4.

Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.

Planque SA, Mitsuda Y, Chitsazzadeh V, Gorantla S, Poluektova L, Nishiyama Y, Ochsenbauer C, Morris MK, Sapparapu G, Hanson CV, Massey RJ, Paul S.

AIDS. 2014 Sep 24;28(15):2201-11. doi: 10.1097/QAD.0000000000000392.

5.

Metal-dependent amyloid β-degrading catalytic antibody construct.

Nishiyama Y, Taguchi H, Hara M, Planque SA, Mitsuda Y, Paul S.

J Biotechnol. 2014 Jun 20;180:17-22. doi: 10.1016/j.jbiotec.2014.03.026. Epub 2014 Apr 1.

6.

Physiological IgM class catalytic antibodies selective for transthyretin amyloid.

Planque SA, Nishiyama Y, Hara M, Sonoda S, Murphy SK, Watanabe K, Mitsuda Y, Brown EL, Massey RJ, Primmer SR, O'Nuallain B, Paul S.

J Biol Chem. 2014 May 9;289(19):13243-58. doi: 10.1074/jbc.M114.557231. Epub 2014 Mar 19.

7.

Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils.

Phay M, Blinder V, Macy S, Greene MJ, Wooliver DC, Liu W, Planas A, Walsh DM, Connors LH, Primmer SR, Planque SA, Paul S, O'Nuallain B.

Rejuvenation Res. 2014 Apr;17(2):97-104. doi: 10.1089/rej.2013.1524.

PMID:
24164623
8.

Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.

Planque SA, Mitsuda Y, Nishiyama Y, Karle S, Boivin S, Salas M, Morris MK, Hara M, Liao G, Massey RJ, Hanson CV, Paul S.

J Immunol. 2012 Dec 1;189(11):5367-81. doi: 10.4049/jimmunol.1200981. Epub 2012 Oct 22.

9.

Nature and nurture of catalytic antibodies.

Paul S, Planque SA, Nishiyama Y, Hanson CV, Massey RJ.

Adv Exp Med Biol. 2012;750:56-75. doi: 10.1007/978-1-4614-3461-0_5.

PMID:
22903666
10.

Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.

Sapparapu G, Planque SA, Nishiyama Y, Foung SK, Paul S.

J Biol Chem. 2009 Sep 4;284(36):24622-33. doi: 10.1074/jbc.M109.011858. Epub 2009 Jun 19.

11.

A covalent HIV vaccine: is there hope for the future?

Paul S, Planque SA, Nishiyama Y, Hanson CV.

Future Virol. 2009;4(1):7-10. No abstract available.

Supplemental Content

Loading ...
Support Center